Treatment of COVID-19 Pneumonia in Ambulatory Patients at High Risk for Progression to Severe Disease

This protocol addresses a clinically urgent subgroup: ambulatory patients with mild-to-moderate COVID-19 who are maintaining adequate oxygenation on room air but carry a profile placing them at high risk for deterioration to severe disease.

Clinical Scenario

The patient is ambulatory with mild-to-moderate COVID-19 — oxygen saturation above 94% on room air, without supplemental oxygen requirement. Despite preserved oxygenation at presentation, a high-risk profile for progression to severe disease makes early intervention the clinical priority.

Treatment Approach

Evidence-based management centres on initiating early antiviral or neutralizing-antibody therapy after symptom onset, with the optimal agent determined by individual clinical factors.

Full selection criteria, the complete therapeutic algorithm, and regimen details are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciac724

Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.
In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.
Among ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests treatment with anti–SARS-CoV-2 monoclonal antibodies with activity against the predominant regional variants within 7 days of symptom onset rather than no anti–SARS-CoV-2 monoclonal antibodies.

View source ↗